
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AG-80308
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AG-80308 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of inflammation associated with Dry Eye Disease (DED).
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 19, 2023
Lead Product(s) : AG-80308
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AG-73305
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Recipient : AffaMed Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AG-73305 is a humanized, bi-specific Fc-fusion protein designed to simultaneously block VEGFs and integrins for the treatment of DME, nAMD, RVO, and other retinal diseases and contains a VEGF-trap and a disintegrin that blocks various key integrin recept...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : AG-73305
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Recipient : AffaMed Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AG-73305
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AG-73305 is a humanized, bi-specific Fc-fusion protein designed to simultaneously block VEGFs and integrins for the treatment of DME, nAMD, RVO, and other retinal diseases and contains a VEGF-trap and a disintegrin that blocks various key integrin recept...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : AG-73305
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AG-80308
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of AG-80308 in Dry Eye Patients
Details : AG-80308 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : AG-80308
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AG-73305
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Lexitas
Deal Size : Inapplicable
Deal Type : Inapplicable
AG-73305 Single Ascending Dose Cohort Study in DME
Details : AG-73305 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : AG-73305
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Lexitas
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AG-86893
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
Details : AG-86893 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pterygium.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 23, 2018
Lead Product(s) : AG-86893
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
